MIN-117 CAS : 310392-93-9 for the treatment of major depressive disorder

MIN-117 is a serotonin-dopamine modulator developed by Minerva Neuroscience for the treatment of major depressive disorder. Its mechanism of action targets the binding of receptors and transporters, including: alpha- 1a receptors; alpha-1B receptors; 5-HT2A receptors; SERT (serotonin transporter); and DAT (dopamine transporter). Specifically, MIN-117 was shown to be a 5-HT1A and 5-HT2A antagonist; serotonin and dopamine reuptake inhibitor; and alpha- 1a and alpha- 1b adrenergic receptor modulator.

Minerva Neuroscience suggests that MIN-117 is designed to address uncontrolled symptoms in patients with major depressive disorder with co-morbid anxiety or anxiety symptoms. The developers hypothesize that MIN-117 will be faster responding, safer, and better tolerated than most antidepressants currently on the market. Clinical trials of MIN-117 as an intervention for depression are currently in Phase II.